Associate Professor David Croucher
Associate Professor David Croucher completed his undergraduate studies and PhD research at the University of Wollongong, followed by a post-doctoral position at the Garvan Institute of Medical Research, focusing on the functional characterisation of individual proteins in the behaviour of cancer cells. Pursuing the idea that these cancer-related proteins do not act in isolation, but are instead embedded within dynamic networks, David undertook a second post-doctoral position at Systems Biology Ireland in University College Dublin. After establishing a research group at Systems Biology Ireland, David received a Future Research Leader grant from Cancer Institute NSW and returned to Garvan as head of the Network Biology group. His research group now focuses on combining computational modelling with novel proteomic and single-cell technologies to investigate how alterations in dynamic signalling networks can lead to tumour progression and therapeutic resistance.
- 2005Cancer Institute Research Scholar Award - Cancer Institute NSW
- 2006Premiers Award for Outstanding Cancer Research Scholar - Cancer Institute NSW
- 2007Cancer Institute Early Career Development Fellowship - Cancer Institute NSW
- 2012Starting Investigator Research Grant - Science Foundation Ireland and Marie Curie Actions COFUND
- 2014Future Research Leader Fellowship - Cancer Institute NSW
- 2015Young Garvan Award
- 2017Collaboration Achievement Award - Irish Laboratory Awards
- 2020The Elaine Henry NBCF Fellowship
- 2023Science advances10.1126/sciadv.abp8314
Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma.
Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma.
- 2019Breast cancer research : BCR10.1186/s13058-019-1127-y
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.
- 2016Science signaling10.1126/scisignal.aaf0793
Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers.
- 2015Science signaling10.1126/scisignal.aab0990
Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients.